It seems to be like I used to be unsuitable about Sellas Life Sciences and its experimental blood most cancers immunotherapy.
On Tuesday, Sellas mentioned the remedy, known as galinpepimut-S, lowered the danger of dying by 41% in comparison with customary remedy for sufferers with a complicated stage of acute myeloid leukemia — an consequence that achieved the principle aim of a Section 3 scientific trial, the corporate mentioned.
STAT Plus: A Sellas immunotherapy research, lengthy delayed, will finish in failure
In a column revealed in September, I predicted galinpepimut would fail to delay survival within the Section 3 research.

This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans

